{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:18Z","timestamp":1753891038663,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>SARS-CoV-2 vaccination has been recommended for liver transplant (LT) recipients. However, our understanding of inactivated vaccine stimulation of the immune system in regulating humoral and cellular immunity among LT recipients is inadequate. Forty-six LT recipients who received two-dose inactivated vaccines according to the national vaccination schedule were enrolled. The clinical characteristics, antibody responses, single-cell peripheral immune profiling, and plasma cytokine\/chemokine\/growth factor levels were recorded. Sixteen (34.78%) LT recipients with positive neutralizing antibody (nAb) were present in the Type 1 group. Fourteen and 16 LT recipients with undetected nAb were present in the Type 2 and Type 3 groups, respectively. Time from transplant and lymphocyte count were different among the three groups. The levels of anti-RBD and anti-S1S2 decreased with decreasing neutralizing inhibition rates. Compared to the Type 2 and Type 3 groups, the Type 1 group had an enhanced innate immune response. The proportions of B, DNT, and CD3+CD19+ cells were increased in the Type 1 group, whereas monocytes and CD4+ T cells were decreased. High CD19, high CD8+CD45RA+ cells, and low effector memory CD4+\/na\u00efve CD4+ cells of the T-cell populations were present in the Type 1 group. The Type 1 group had higher concentrations of plasma CXCL10, MIP-1 beta, and TNF-alpha. No severe adverse events were reported in all LT recipients. We identified the immune responses induced by inactivated vaccines among LT recipients and provided insights into the identification of immunotypes associated with the responders.<\/jats:p>","DOI":"10.3389\/fimmu.2022.954177","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T12:50:17Z","timestamp":1663159817000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines"],"prefix":"10.3389","volume":"13","author":[{"given":"Binwei","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yabo","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1097","article-title":"Coronavirus disease 2019 in solid organ transplant: A multicenter cohort study","volume":"73","author":"Kates","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15941","article-title":"COVID-19 in solid organ transplant recipients: Initial report from the US epicenter","volume":"20","author":"Pereira","year":"2020","journal-title":"Am J Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.032","article-title":"EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients","volume":"74","author":"Cornberg","year":"2021","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31751","article-title":"American Association for the study of liver diseases expert panel consensus statement: Vaccines to prevent coronavirus disease 2019 infection in patients with liver disease","volume":"74","author":"Fix","year":"2021","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":":e151178","DOI":"10.1172\/JCI151178","article-title":"Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients","volume":"131","author":"Stock","year":"2021","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1111\/ajt.16818","article-title":"Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients","volume":"21","author":"Schmidt","year":"2021","journal-title":"Am J Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003900","article-title":"SARS-CoV-2 messenger RNA vaccine immunogenicity in solid organ transplant recipients with prior COVID-19","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients","volume":"21","author":"Hall","year":"2021","journal-title":"Am J Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13361","article-title":"Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients","volume":"290","author":"Holden","year":"2021","journal-title":"J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16615","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.008","article-title":"Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases","volume":"75","author":"Thuluvath","year":"2021","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":":404","DOI":"10.3390\/vaccines8030404","article-title":"COVID-19: Mechanisms of vaccination and immunity","volume":"8","author":"Speiser","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/vaccines8040649","article-title":"COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response","volume":"8","author":"Jain","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581807","article-title":"An effective COVID-19 vaccine needs to engage t cells","volume":"11","author":"Sauer","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00625-9","article-title":"T Cell-oriented strategies for controlling the COVID-19 pandemic","volume":"21","author":"Noh","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa462","article-title":"Downregulated gene expression spectrum and immune responses changed during the disease progression in patients with COVID-19","volume":"71","author":"Ouyang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109504","article-title":"Systemic IL-15, IFN-gamma, and IP-10\/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients","volume":"36","author":"Bergamaschi","year":"2021","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614436","article-title":"Longitudinal profiling of antibody response in patients with COVID-19 in a tertiary care hospital in beijing, china","volume":"12","author":"Feng","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-4939-0928-5_7","article-title":"A useful guide for analysis of immune markers by fluorochrome (Luminex) technique","volume":"1172","author":"Faresjo","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1038\/s41467-017-01689-9","article-title":"Visual analysis of mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types","volume":"8","author":"van Unen","year":"2017","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent immune response to the Biontech\/Pfizer BNT162b2 coronavirus disease 2019 vaccination","volume":"73","author":"Muller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100178","article-title":"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine","volume":"9","author":"Stumpf","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888385","article-title":"Risk factors for weak antibody response of SARS-CoV-2 vaccine in adult solid organ transplant recipients: A systemic review and meta-analysis","volume":"13","author":"Zong","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.928542","article-title":"MMF\/MPA is the main mediator of a delayed humoral response with reduced antibody decline in kidney transplant recipients after SARS-CoV-2 mRNA vaccination","volume":"9","author":"Stumpf","year":"2022","journal-title":"Front Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":":eabc8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.06.009","article-title":"Antibody and b cell responses to SARS-CoV-2 infection and vaccination","volume":"29","author":"Roltgen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22042","article-title":"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes, and half-dead lymphocytes","volume":"102","author":"Eksioglu-Demiralp","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.681","article-title":"Discovery of CD3(+) CD19(+) cells, a novel lymphocyte subset with a potential role in human immunodeficiency virus-mycobacterium tuberculosis coinfection, using mass cytometry","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2020.01.007","article-title":"Discovery and characteristics of b cell-like T cells: A potential novel tumor immune marker","volume":"220","author":"Liu","year":"2020","journal-title":"Immunol Lett"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFNgamma: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02692","article-title":"Defining memory CD8 t cell","volume":"9","author":"Martin","year":"2018","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1038\/ncomms6377","article-title":"Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2","volume":"5","author":"McKinstry","year":"2014","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: Positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2011.06.001","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(02)00045-x","article-title":"Macrophage inflammatory protein-1","volume":"13","author":"Menten","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3109\/01902149409031733","article-title":"Macrophage inflammatory proteins: Biology and role in pulmonary inflammation","volume":"20","author":"Driscoll","year":"1994","journal-title":"Exp Lung Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-022-00373-7","article-title":"Robust induction of b cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine","volume":"8","author":"Liu","year":"2022","journal-title":"Cell Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.954177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T12:50:20Z","timestamp":1663159820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.954177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2022.954177"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.954177","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"article-number":"954177"}}